Pharmacovigilance Case Processor Interview Questions for Freshers
Contents
- What a fresher should show in an interview
- Interview questions and sample answers
- PV and case intake
- Processing, quality, and follow-up
- Prioritisation and judgement
- Scenario and teamwork questions
- A fictional practice case
- How to prepare in one week
- Frequently asked questions
- Can a fresher apply for pharmacovigilance case processor roles?
- Does a case processor decide whether a medicine caused an event?
- Do all countries use the same reporting timelines?
- Which sources should I review before an interview?
- References
In short: A pharmacovigilance case processor turns incoming safety information into a clear, traceable case record for assessment and reporting. These interview questions help freshers practise explaining intake, data quality, follow-up, and escalation without claiming medical or regulatory decisions that belong to trained reviewers.
What a fresher should show in an interview
Interviewers usually want to see careful reading, clear writing, confidentiality, and willingness to follow the current procedure. You do not need to pretend that you can make a medical assessment on your own. Explain what you would record, what you would check, and when you would ask a trained colleague for review.
Use the relevant source for the context: ICH E2A (current Step 4 version, 27 October 1994) covers clinical-trial safety data; ICH E2D(R1) (adopted 15 September 2025) covers post-approval case management. E2D(R1) points to local and regional rules for reportability; PvPI guidance gives the Indian context.
Interview questions and sample answers
PV and case intake
1. What does a pharmacovigilance case processor do?
“I receive safety information, organise the reported facts into the required case record, and check that the information is complete and consistent. I follow the applicable procedure and send clinical or regulatory questions to the qualified reviewer rather than making those decisions myself.”
What the interviewer is checking: Whether you understand the processing role and its limits.
2. How would you explain the difference between ICH E2A and ICH E2D?
“E2A (1994) covers clinical-trial safety data; E2D(R1) (2025) covers post-approval case reporting. I would confirm the context, then use the matching guidance and local requirements.”
3. What minimum information would you check for a post-approval ICSR?
“I would check for an adverse event or other observation, a suspect or interacting medicinal product, an identifiable patient, and an identifiable reporter. I would record what is present, flag missing elements, and follow the approved follow-up process instead of filling gaps by assumption. These minimum criteria are set out in ICH E2D(R1), section 2.2 (2025).”
What the interviewer is checking: Whether you can recall the criteria accurately without inventing details.
4. How do you distinguish an adverse event from an adverse drug reaction?
“An adverse event is an untoward medical occurrence that does not by itself establish a product relationship. I would preserve the reporter’s account, use ICH E2A (1994) for a trial context or ICH E2D(R1) (2025) for a post-approval context, and never infer causality from timing alone.”
5. What is the difference between seriousness and severity?
“I would not treat the words as interchangeable. ICH E2A (1994) distinguishes seriousness, which guides regulatory reporting, from severity, which describes intensity; I would use the applicable source and ask the safety reviewer if I was unsure.”
What the interviewer is checking: Whether you avoid classifying a case only from an adjective such as ‘severe’ and know when to escalate.
6. How would you decide whether a reported reaction is expected?
“I would compare the event with the applicable regional product information, using the correct product and version. ICH E2D(R1) (2025), section 2.1.4, explains expectedness in relation to regional or local labelling, so I would not rely on memory or a different market’s label.”
Processing, quality, and follow-up
7. What would you do if an important date is missing?
“I would leave the missing detail clearly identified and check the approved follow-up questions. ICH E2D(R1) (2025), section 6.4, covers follow-up information; I would not estimate a date or change the source account to make the timeline look complete.”
8. How do you check whether a report may be a duplicate?
“I would compare the available patient, event, product, reporter, and date details in the authorised system, while allowing for differences between sources. If the match is uncertain, I would flag it for review rather than merging or deleting a case myself; ICH E2D(R1), section 6.6 (2025), describes duplicate management as part of good case management.”
What the interviewer is checking: Whether you protect case history and avoid making an unauthorised merge decision.
9. How would you write a case narrative?
“I would put the reported facts in a clear sequence and distinguish the reporter’s account from any assessment added by the company. I would use neutral wording, keep relevant dates and product details consistent with the source, and avoid adding a cause that the reporter did not state.”
10. What makes a follow-up request useful?
“I would ask focused questions about missing or useful information, document the attempt, and handle any response under the applicable privacy and case-processing procedure.”
11. What would you do if the source uses an unfamiliar event term?
“I would preserve the original wording and use the controlled terminology and coding rules provided by the employer. I would not choose a medical term from a search result or change the meaning to make the entry look more technical.”
12. What if the product name or strength is unclear?
“I would capture the name as reported, check available identifiers through the approved process, and flag uncertainty or request clarification instead of guessing.”
13. How would you handle inconsistent dates or details?
“I would compare the source documents, note the discrepancy, and ask a focused follow-up question. I would preserve the original in the case history and correct it only through the authorised procedure.”
14. How do you protect patient and reporter information?
“I would use only the information needed for my work and the authorised systems. ICH E2D(R1), section 6 (2025), points to local privacy rules, which I would follow alongside employer access and sharing procedures.”
Prioritisation and judgement
15. How would you prioritise a busy case queue?
“I would follow the team’s prioritisation rules and promptly flag cases needing urgent assessment. ICH E2D(R1), sections 5 and 6.4 (2025), discusses reporting and follow-up; I would check current local requirements for the case.”
16. What would you do if you were unsure about a reporting deadline?
“I would check the current country- and product-specific requirement and the employer’s procedure, then alert the responsible reviewer if the due date was not clear. I would never borrow a deadline from another country or assume that one timeline applies to every type of report.”
17. How do you keep a case handoff traceable?
“I would use the approved system to show what information arrived, what remains unresolved, and who needs to review the next step. Example in-house criterion: a team may use a standard handoff note with the source, outstanding questions, and assigned reviewer; the format is set by the employer.”
18. What would you do if you did not know the answer to a regulatory question?
“I would say what I know, identify the point I need to confirm, and check the current official source or ask the qualified reviewer. I would rather pause and verify than give a confident answer from memory.”
What the interviewer is checking: Whether you recognise the limits of your knowledge and use a safe escalation path.
Scenario and teamwork questions
19. A consumer reports a rash after using a fictional product but gives few details. What do you do?
“I would record the report as given, capture the available patient, product, event, and reporter information, and check the minimum case criteria. I would use the approved follow-up process for missing information and leave causality and reportability for the authorised assessment.”
20. Two different people report the same event for one patient. What would you do?
“I would compare the records carefully and note that the sources may be describing one event. I would flag a possible duplicate for the reviewer and preserve both source details until the authorised duplicate process is complete.”
21. A caller asks you whether the product caused the event. How do you respond?
“I would not give a medical conclusion. Example in-house criterion: I would acknowledge the concern, record the information without bias, and route the question to the designated medical or safety contact under the employer’s procedure.”
22. You notice that the event wording and the seriousness field do not appear to match. What do you do?
“I would not change either field based on my own interpretation. I would check the source information, document the mismatch, and ask the trained reviewer to confirm the classification before the case moves forward.”
23. How do you work with a medical reviewer or safety scientist?
“I would summarise the source facts, missing information, and specific questions. I would keep the record neutral and apply the reviewer’s decision through the approved workflow.”
24. Why should we hire you as a fresher?
“I am careful with details, comfortable asking questions, and willing to learn the company’s systems and procedures. I can explain my reasoning clearly, protect confidential information, and accept feedback when a reviewer asks me to correct or clarify a case.”
A fictional practice case
Use this scenario to practise a concise response. It is fictional and contains no real patient information.
| Information received | Safe processing response |
|---|---|
| A consumer says a fictional product was followed by a skin reaction. The message does not include a date or a reporter callback detail. | Preserve the consumer’s wording, enter the available information in the authorised system, check the minimum criteria in ICH E2D(R1) section 2.2, and flag the missing details for follow-up. Do not assign causality or invent a date. |
In an interview, explain the sequence rather than jumping to a conclusion: capture, check, query, document, and escalate. Example in-house criterion: the employer may require a second-person quality check before a case is submitted; confirm the actual workflow during training.
How to prepare in one week
- Day 1: Read the role description; distinguish pre-approval from post-approval safety reporting.
- Day 2: Review E2D(R1): minimum case criteria, expectedness, follow-up, and duplicates.
- Day 3: Review ICH E2B(R3) and practise explaining why structured data must match its source.
- Day 4: Read current PvPI guidance; note questions to check against local procedures.
- Day 5: Practise fictional case intake and write a neutral narrative without assumptions.
- Day 6: Rehearse five answers and prepare an example of responding to feedback.
- Day 7: Check official references, then prepare an introduction and questions for the interviewer.
For a wider overview of pharmacovigilance jobs for freshers, see the role guide. You can also review regulatory affairs interview questions, compare careers after B.Pharm and D.Pharm, and improve your pharma fresher resume.
Frequently asked questions
Can a fresher apply for pharmacovigilance case processor roles?
Follow the degree and experience requirements in the specific employer’s vacancy notice. The role can be a starting point for graduates, but eligibility varies by employer and position.
Does a case processor decide whether a medicine caused an event?
The processor captures and checks case information under the employer’s process. Assessment and reporting decisions follow the applicable procedure and are reviewed by the people assigned those responsibilities.
Do all countries use the same reporting timelines?
No. ICH E2D(R1) directs readers to regional and local requirements. A candidate should explain how they would verify the right requirement rather than state one deadline for every case.
Which sources should I review before an interview?
Start with ICH E2D(R1) for post-approval case management, the current ICH E2B(R3) materials for structured ICSR exchange, and the current PvPI guidance for India-specific marketing-authorisation-holder processes.
References
- International Council for Harmonisation (ICH), Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, E2A, current Step 4 version dated 27 October 1994. Official ICH PDF.
- ICH, E2B(R3) Individual Case Safety Report (ICSR) Specification and Related Files, Implementation Guide package version 1.11, January 2026. Official ICH page.
- ICH, Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports, E2D(R1), final version adopted 15 September 2025. Official ICH PDF.
- National Coordination Centre–Pharmacovigilance Programme of India (PvPI), Indian Pharmacopoeia Commission, with CDSCO, Pharmacovigilance Guidance Document for Marketing Authorization Holders of Pharmaceutical Products, version 2.0 (2024). Official PDF.
- CDSCO, Pharmacovigilance Programme of India (PvPI) (accessed 8 November 2026).
Related articles
Clinical Data Management Careers for Pharmacy Graduates
Explore clinical data management careers for pharmacy graduates, entry-level roles, core skills, study data workflows and a practical fresher preparation plan.
ALCOA+ Data Integrity in Pharma: Complete Guide and Checklist
ALCOA+ data integrity explained for pharma: attributes, paper and electronic records, audit trails, shared logins, hybrid systems, FDA themes and a self-audit checklist.
Pharmacovigilance Jobs for Freshers: Roles, Skills, Career
Pharmacovigilance jobs for freshers in India: what PV is, entry roles, key terms, skills, qualifications, career path and how to avoid fake PV courses.
Revised Schedule M Explained: A Summary for Pharma Freshers
Revised Schedule M explained for pharma freshers: what G.S.R. 922(E) of 2023 changed, the key GMP themes, who must comply and what it means for daily work in a plant.